Abstract
We report a successful treatment with rituximab in a patient with CANOMAD neuropathy resistant to previous therapy. The titers of anti-disialosyl antibodies were decreased 3 months after the beginning of the treatment and the sensory ataxia clearly improved after 9 months of therapy.
MeSH terms
-
Aged
-
Anemia, Hemolytic, Autoimmune / complications
-
Anemia, Hemolytic, Autoimmune / drug therapy*
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, Surface / immunology
-
Female
-
Humans
-
Immunoglobulin M / blood
-
Immunologic Factors / therapeutic use*
-
Oligosaccharides / immunology
-
Ophthalmoplegia / complications
-
Ophthalmoplegia / drug therapy*
-
Polyradiculoneuropathy / complications
-
Polyradiculoneuropathy / drug therapy*
-
Rituximab
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, Surface
-
Immunoglobulin M
-
Immunologic Factors
-
Oligosaccharides
-
disialosyl-T antigen, human
-
Rituximab